The company — located in Australia and Eagan, Minnesota — aims to raise funds through the IPO to advance the development of its DurAVR transcatheter heart valve technology.
Anteris’ IPO consists of 14.8 million shares of common stock, with an additional 2.22 million shares available to underwriters under a 30-day option. The company has applied to list its shares on the Nasdaq Global Market under the AVR ticker.
Proceeds from the IPO will primarily support the development of the DurAVR transcatheter heart valve and the start of a global pivotal study that will target severe aortic stenosis treatment. Any remaining funds will be allocated to working capital, corporate purposes, and the repayment of convertible note facility obligations.
More about Anteris’ technology
The DurAVR is a transcatheter heart valve Anteris designed to treat aortic stenosis. It is one of the first transcatheter aortic valve replacements to use a single piece of bioengineered tissue. The biomimetic valve is shaped to replicate the performance of a healthy human aortic valve.
DurAVR is made using Anteris’ patented anti-calcification tissue technology, Adapt Tissue. Adapt has been used clinically for over 10 years and is distributed to over 55,000 patients worldwide.
According to the company, the heart valve is delivered through the ComASUR Delivery System, which provides controlled deployment and accurate placement with balloon-expandable delivery. Anteris designed the delivery system to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.
